Five-year safety evaluation of maraviroc in HIV-1-infected treatment-experienced patients

Roy M Gulick, Gerd Fatkenheuer, Robert Burnside, W David Hardy, Mark R Nelson, James Goodrich, Geoffrey Mukwaya, Simon Portsmouth, Jayvant R Heera, Roy M Gulick, Gerd Fatkenheuer, Robert Burnside, W David Hardy, Mark R Nelson, James Goodrich, Geoffrey Mukwaya, Simon Portsmouth, Jayvant R Heera

Abstract

Background: Maraviroc is unique among approved antiretroviral drugs in targeting the host-cell chemokine coreceptor type-5 receptor. With its novel mechanism of action, we sought to describe the 5-year safety profile of maraviroc.

Methods: Two large phase 3 studies of maraviroc enrolled HIV-infected treatment-experienced patients and followed them up for 5 or more years. Survival and selected clinical end points were identified and assessed.

Results: A total of 938 enrolled patients received maraviroc-containing regimens. Rates of death and selected clinical events (eg, hepatic failure, malignancy, and myocardial infarction) were low during follow-up.

Conclusions: Maraviroc was generally safe in treatment-experienced participants for >5 years.

Trial registration: ClinicalTrials.gov NCT00098306 NCT00098722.

Figures

FIGURE 1
FIGURE 1

References

    1. Fätkenheuer G, Pozniak AL, Johnson MA, et al. Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1. Nat Med. 2005;11:1170–1172
    1. Caldwell DJ, Evans JD. Developing clinical role of a CCR5 co-receptor antagonist in HIV-1 infection. Expert Opin Pharmacother. 2008;9:3231–3242
    1. Currier J, Lazzarin A, Sloan L, et al. Antiviral activity and safety of aplaviroc with lamivudine/zidovudine in HIV-infected, therapy-naive patients: the ASCENT (CCR102881) study. Antivir Ther. 2008;13:297–306
    1. Wilkin TJ, Su Z, Krambrink A, et al. Three-year safety and efficacy of vicriviroc, a CCR5 antagonist, in HIV-1-infected treatment-experienced patients. J Acquir Immune Defic Syndr. 2010;54:470–476
    1. Caseiro MM, Nelson M, Diaz RS, et al. Vicriviroc plus optimized background therapy for treatment-experienced subjects with CCR5 HIV-1 infection: final results of two randomized phase III trials. J Infect. 2012;65:326–335
    1. Gulick RM, Lalezari J, Goodrich J, et al. Maraviroc for previously treated patients with R5 HIV-1 infection. N Engl J Med. 2008;359:1429–1441
    1. Hardy WD, Gulick RM, Mayer H, et al. Two-year safety and virologic efficacy of maraviroc in treatment-experienced patients with CCR5-tropic HIV-1 infection: 96-week combined analysis of MOTIVATE 1 and 2. J Acquir Immune Defic Syndr. 2010;55:558–564
    1. Rockstroh J, deJesus E, Saag M, et al. Long-term safety and efficacy of raltegravir (RAL)-based versus efavirenz (EFV)-based combination therapy in treatment-naive HIV-1-infected patients: final 5-year double-blind results from STARTMRK [abstract LBPE19]. Geneva, Switzerland, International AIDS Society; In: Program and Abstracts of the XIX International AIDS Conference (AIDS 2012); 2012;Washington, DC
    1. Ayoub A, Alston S, Goodrich J, et al. Hepatic safety and tolerability in the maraviroc clinical development program. AIDS. 2010;24:2743–2750
    1. Walmsley S, Campo R, Goodrich J, et al. Low risk of malignancy with maraviroc in treatment-experienced (TE) and treatment-naïve (TN) patients across the maraviroc clinical development program [abstract TuPE0157]. Geneva, Switzerland, International AIDS Society; Program and Abstracts of the XVIII International AIDS Conference; 2010; Vienna, Austria
    1. Steigbigel RT, Cooper D, Eron J, et al. 96-Week Results from BENCHMRK 1 and 2, Phase III Studies of Raltegravir in Patients Failing ART with Triple-class-resistant HIV [abstract 571b]. Alexandria, VA: CROI; Programs and Abstracts of the 16th Conference on Retroviruses and Opportunistic Infections; 2009; Montreal, Canada
    1. Portsmouth S, Burnside R, Lazzarin A, et al. Incidence of Ischemic Cardiovascular Events in the Maraviroc Clinical Development Program [abstract P65]. Cheshire, UK: Tenth International Congress on Drug Therapy in HIV Infection. Program and Abstracts of the 10th International Congress on Drug Therapy in HIV Infection; 2010; Glasgow, Scotland
    1. Worm SW, Sabin C, Weber R, et al. Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D:A:D) study. J Infect Dis. 2010;201:318–330
    1. Klein D, Hurley L, Quesenberry C, et al. Hospitalizations for CHD and MI Among Northern California HIV+ and HIV- Men: Changes in Practice and Framingham Risk Scores [abstract 737]. Alexandria, VA: Foundation for Retrovirology and Human Health; In: Program and Abstracts of the 13th Conference on Retroviruses and Opportunistic Infections; 2006; Denver, CO
    1. Lazzarin A, Lalezari J, Reynes J, et al. Maraviroc (MVC) expanded access program (EAP): outcomes in treatment-experienced patients receiving MVC with or without other novel agents [abstract H-209]. Washington, DC: American Society for Microbiology; In: Final Program of the 50th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy; 2010; Boston, MA

Source: PubMed

Patrocinadores e Colaboradores

Condições médicas

Intervenções de drogas

3
Se inscrever